CM
ADMA icon

Caption Management’s ADMA Biologics ADMA Stock Holding History

Caption Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3M Buy
1,148,400
+1,098,400
+2,197% +$17.3M 0.06% 328
2025
Q4 		$912K Sell
50,000
-282,500
-85% -$4.76M 0.01% 1091
2025
Q3 		$4.87M Buy
332,500
+35,000
+12% +$600K 0.04% 498
2025
Q2 		$5.42M Buy
+297,500
New +$6.07M 0.06% 383

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Caption Management's ADMA Position: Q1 2026 in Review

Caption Management opened a new position in ADMA Biologics (ADMA) in Q1 2026: 660,000 shares worth $5.95M. The stake represents 0.03% of the portfolio and ranks #484 among its holdings. This is a return to the name: Caption Management previously reported a position in ADMA as recently as Q3 2025.

Caption Management first reported a position in ADMA in Q2 2025 and has held it in 3 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Caption Management held 660,000 shares of ADMA Biologics worth $5.95M as of Q1 2026.
  • ADMA Biologics was a new Caption Management position in Q1 2026.
  • ADMA Biologics made up 0.03% of Caption Management's portfolio in Q1 2026, its #484 holding.
  • Caption Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 3 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.